Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T18:31:16.346Z.
Calculation as of: 2026-10-06T18:31:16.346Z.
Quote observation: 2026-10-06T18:29:40.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: d443e069440aa0ac5a32f25afa0d38c48efe58a411ec60778b8439bb1c5cf92a
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Eledon Pharmaceuticals, Inc.
Market Cap
$189.87M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$192.20M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$183.94M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$177.57M
EV/EBITDA Ratio
N/A
TTM Avg
0.27x
3Y Avg
0.27x
5Y Avg
0.27x
Market Cap
$181.47M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$178.59M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Eledon Pharmaceuticals, Inc. (ELDN) | $189.87M | N/A | N/A | N/A | N/A |
| RxSight, Inc. (RXST)vs › | $192.29M | N/A | N/A | N/A | N/A |
| Zentalis Pharmaceuticals, Inc. (ZNTL)vs › | $192.20M | N/A | N/A | N/A | N/A |
| AN2 Therapeutics, Inc. (ANTX)vs › | $183.86M | N/A | N/A | N/A | N/A |
| Canton Strategic Holdings Inc (CNTN)vs › | $183.94M | N/A | N/A | N/A | N/A |
| Yarrow Bioscience Inc (YARW)vs › | $177.57M | N/A | 0.27x | 0.27x | 0.27x |
| Oramed Pharmaceuticals Inc. (ORMP)vs › | $181.47M | N/A | N/A | N/A | N/A |
| Surrozen, Inc. (SRZN)vs › | $199.58M | N/A | N/A | N/A | N/A |
| Compass Therapeutics, Inc. (CMPX)vs › | $178.59M | N/A | N/A | N/A | N/A |
| Alector, Inc. (ALEC)vs › | $200.96M | N/A | 16.55x | 16.55x | 16.55x |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
